
RPG Life Sciences acquires Actis and Raghava for ₹215 crore to boost API business
The story in brief
RPG Life Sciences acquired Actis Generics for ₹80 crore and Raghava Life Sciences for ₹135 crore, boosting its manufacturing capacity to 505 KL, product portfolio to 45, and customer base to over 250. The company plans to expand through new customers, geographic growth, and integration, while remaining debt-free.